Get the Daily Brief
Latest Biotech News
Inherited variant curbs clonal hematopoiesis, reduces leukemia risk – Science
A GWAS meta‑analysis of more than 640,000 individuals, led by Vijay G. Sankaran’s lab at Harvard Medical School and published in Science, identified a rare noncoding variant (rs17834140‑T) that...
Engineered T cells gain precision – ex‑vivo platforms test immunotherapy
Two complementary advances target immunotherapy precision: first, researchers led by Cabezas‑Caballero engineered co‑signaling receptors that reduce T‑cell off‑target cross‑reactivity and improve...
AbbVie pays $1.1B — Gains ex‑China rights to Zelgen T‑cell engager
AbbVie signed a deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006) in a pact valued at up to $1.1 billion. Under the agreement, AbbVie...
Third FDA CRL... Outlook Therapeutics’ ONS‑5010 rejected again
The FDA issued a third complete response letter (CRL) to Outlook Therapeutics for ONS‑5010, its bevacizumab biosimilar/formulation aimed at treating wet age‑related macular degeneration. The...
Transcenta licenses HiCB platform to EirGenix: upfronts and milestones
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform to support continuous perfusion and integrated hybrid continuous...
Insilico posts big gain after Hong Kong listing – Finance report
Insilico Medicine recorded a strong market response following its Hong Kong listing, with finance reporting pointing to a notable post‑IPO valuation uptick. BioCentury’s finance roundup...
Psithera spins out of Roivant: $47.5M Series A and new CEO
Psithera Inc. completed a spin‑out from Roivant Sciences, rebranding from Psivant Therapeutics and announcing a $47.5 million Series A financing alongside the appointment of Eric Shaff as...
Neuro biotech Nido shuts down – Phase 2 readout disappoints
Nido Biosciences announced it will close after its lead neurological disease candidate failed to produce meaningful benefit in a midstage (phase 2) study. The company’s decision ends a five‑year...
St. Jude unveils method to detect base‑editor off‑targets: improves precision assessments
St. Jude Children’s Research Hospital published a new method to better detect small off‑target changes produced by base editors, addressing a key safety challenge in precision genome editing. The...
Single‑strand deaminase powers AIM RNA editor: precise, controllable edits
A team reported an Adjustable RNA Information Manipulation (AIM) platform that uses a single‑strand deaminase to enable precise, site‑specific RNA editing, marking a step forward for transient...
Venetoclax + palbociclib — OHSU finds combo overcomes AML resistance
Oregon Health & Science University researchers identified a drug combination—venetoclax (BCL2 inhibitor) plus palbociclib (CDK4/6 inhibitor)—that produced stronger, more durable anti‑leukemia...
Inherited variant curbs clonal hematopoiesis: lowers blood cancer risk
A GWAS meta‑analysis of more than 640,000 individuals identified a rare noncoding variant, rs17834140‑T, that substantially lowers the risk of clonal hematopoiesis of indeterminate potential...
AbbVie buys ex-China rights to DLL3 trispecific: $1.1B pact
AbbVie signed a deal to acquire ex‑China rights to Zelgen Biopharmaceuticals’ trispecific T‑cell engager alveltamig (ZG‑006), committing $100 million up front and up to $1.075 billion in...
Insilico rallies after Hong Kong IPO: finance boost
Insilico Medicine saw a strong post‑listing performance in Hong Kong, delivering a notable market gain that buoyed investor sentiment in AI‑drug discovery firms. The company’s listing was...
Harmeier returns to lead Roche Venture Fund: leadership reset
Roche appointed Harmeier to return as head of its venture fund, reversing a prior leadership change and signaling renewed focus on external innovation sourcing. The BioCentury management brief...
Third FDA CRL sinks Outlook’s ONS‑5010... stock collapses
Outlook Therapeutics received a third complete response letter (CRL) from the U.S. FDA for its bevacizumab biosimilar ONS‑5010 for wet age‑related macular degeneration, prompting a sharp share...
Psithera spins out of Roivant with $47.5M — immune focus
Psithera Inc. completed a spinout from Roivant, rebranding and securing $47.5 million in Series A financing to advance small‑molecule programs against immune and inflammatory targets. The company...
Transcenta licenses continuous‑biomanufacturing tech to EirGenix: CDMO pact
Transcenta Therapeutics granted EirGenix a non‑exclusive license to its highly intensified continuous bioprocessing (HiCB) platform, enabling EirGenix to offer continuous perfusion and integrated...
Nido Biosciences shutters after phase‑2 miss — neuro biotech fallout
Nido Biosciences announced closure following a disappointing midstage study readout for its lead neurological candidate, ending five years of operations. The company’s phase‑2 failure underscores...
Ultragenyx to cut costs after phase‑3 failures — major restructuring planned
Ultragenyx reported two failed phase‑3 trials in brittle bone disease and announced plans for significant cost‑cutting to rebalance its portfolio and preserve cash. The company’s decision follows...